Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13

NCT00847145 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00847145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00847145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2009
Completion date
August 31, 2010
Enrollment
2,249 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease